Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal MNJ (Malang Neurology Journal) Magna Neurologica
Tan, Kenneth
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Attenuation of Neuronal Tissue Damage in Ischemic Stroke by Tat-NR2Bct-CTM and Tat-NR2B9c Benedictus, Benedictus; Tan, Kenneth; Pratama, Vincent Kurniawan Putra; Sulastyo, Jonathan Daniel
Magna Neurologica Vol. 1 No. 2 (2023): July
Publisher : Department of Neurology Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/magnaneurologica.v1i2.647

Abstract

Background: Worldwide, stroke accounts for 15 million cases annually. Despite improved understanding of its pathophysiology, an effective treatment is yet to be available. Objective: This review aims to expound ischemic stroke pathophysiology from a bio-molecular perspective, and present two peptides, namely Tat-NR2B9c and Tat-NR2Bct-CTM, which has been proven to attenuate neuronal tissue damage in ischemic stroke. Methods: Scoping review of several electronic databases: PubMed, Medline, Researchgate, NCBI, SpringerLink, and Google scholar. Search query included: ischemic stroke, NR2B, DAPK1, nNOS, NOX, Tat-NR2Bct-CTM and Tat-NR2B9c. Results:  It is recognizable in a sense, that the pathophysiology pivots on the NR2B-DAPK1 and PSD-95-NR2B interactions. Tat-NR2Bct-CTM and Tat-NR2B9c thwarts NR2B-DAPK1 and PSD-95-NR2B interactions, respectively. These peptides show significant reliability, with the former capable of reducing free DAPK1 by 92,85%, and the latter, the first stroke treatment in two decades to reach Phase 3 clinical trials. Conclusion: These results strongly support Tat-NR2Bct-CTM and Tat-NR2B9c as effective means to reduce neuronal tissue damage in ischemic stroke.
COMPARISON OF EFFICACY BETWEEN EDARAVONE AND RILUZOLE COMBINATION THERAPY FOR PATIENT WITH AMYOTROPHIC LATERAL SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS Budianto, Pepi; Mirawati, Diah Kurnia; B, Benedictus; Tan, Kenneth; Hafizhan, Muhammad; Putra, Stefanus Erdana
MNJ (Malang Neurology Journal) Vol. 11 No. 1 (2025): January
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.01.13

Abstract

Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neuromuscular disease with a survival period of less than 5 years. Although the past decade has shown a major growth of interest in Edaravone research due to its superior efficacy, a growing number of research done on Riluzole combinations for ALS therapy. Objective: A systematic review is needed to compare the patient outcomes as shown in the ALS functional rating scale (ALSFRS-R) of Edaravone and Riluzole combinations. Methods: This research is a systematic review from PubMed, ProQuest, and Science Direct. The studies included were randomized controlled trials (RCT) and post-hoc analysis of RCT published from 2012 to 2023. This research included 16 studies (11 RCT studies and 5 post-hoc studies of RCT). The studies discussed the patient population, side effects, and ALSFRS-R scores. Results: Edaravone showed better efficacy than Riluzole combination in maintaining ALSFRS-R score with mean difference between Edaravone (MD=2.19, 95% CI: 0.42-3.96, p=0.02) and Riluzole (MD=1.67, 95% CI: -0.19-3.52, p=0.08). The meta-analysis showed heterogeneity in both Edaravone (I2=90%, p<0.00001) and Riluzole (I2=77%, p=0.004) studies. Conclusion: The results conclusively showed that Edaravone was more efficacious than the explored Riluzole combinations so far. Nevertheless, Riluzole-Masitinib showed promising results to be further explored.
Co-Authors B, Benedictus Benedictus Benedictus, Benedictus Budianto, Pepi Diah Kurnia Mirawati Hafizhan, Muhammad Pratama, Vincent Kurniawan Putra Stefanus Erdana Putra Sulastyo, Jonathan Daniel